Literature DB >> 9808582

Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6.

M S Mahmoud1, H Ishikawa, R Fujii, M M Kawano.   

Abstract

Recently, there has been an increasing interest in the expression pattern and biological significance of the CD45 molecule in myeloma cells. In this study, we have further defined the phenotypic pattern of CD45 expression on myeloma cells. Using a panel of myeloma cell lines, we showed that CD45 showed a remarkably heterogeneous pattern of expression. Whereas some cell lines were CD45(+) and others were CD45(-), the U-266 cell line, although predominantly CD45(-), still had a considerable subpopulation of CD45(+) cells. Among the myeloma cell lines examined, there was a direct correlation between interleukin-6 (IL-6) dependency and CD45 positivity. Moreover, we showed that IL-6 stimulation led to the induction of expression of CD45 and cellular proliferation. Using independent experimental approaches, we could show that the IL-6-induced effects were closely linked to CD45 expression. First, sorting out CD45(+) and CD45(-) subsets of U-266 cell line followed by IL-6 stimulation, only the CD45(+) cells showed a proliferative advantage after IL-6 stimulation. Second, IL-6 stimulation of sorted CD45(-) cells was gradually followed by phenotypic conversion to CD45(+) cells that started after 2 days as judged by the detection of CD45 mRNA by reverse transcription polymerase chain reaction (RT-PCR) and immunophenotypic analysis by flow cytometry. Withdrawal of IL-6 from the medium led to gradual loss of CD45 expression in CD45(+) flow-sorted U-266 cells. Third, the use of vanadate, a potent inhibitor of protein tyrosine phosphatase (PTP), abrogated the IL-6-induced proliferation in the CD45(+) myeloma cells. On the other hand, cellular proliferation induced by IL-6 was not affected by the serine-threonine phosphatase inhibitor okadaic acid. Our data show that the expression pattern of CD45 in myeloma cell lines is heterogeneous and show for the first time that CD45 expression can be induced by IL-6 stimulation. Finally, these data shed some light on the biological role of CD45 in myeloma by determining the proliferative population among myeloma cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808582

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  An integrated technique for identification of differential genes expressed in patients with cancer.

Authors:  Shouxin Li; Shangqin Liu; Xiaomei Lei
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

Review 2.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

3.  The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.

Authors:  Shmuel Yaccoby
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

4.  A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Authors:  Jérôme Moreaux; Bernard Klein; Régis Bataille; Géraldine Descamps; Sophie Maïga; Dirk Hose; Hartmut Goldschmidt; Anna Jauch; Thierry Rème; Michel Jourdan; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

5.  Growth mechanism of human myeloma cells by interleukin-6.

Authors:  Michio M Kawano; Hideaki Ishikawa; Naohiro Tsuyama; Saeid Abroun; Shangqin Liu; Fu-Jun Li; Ken-ichiro Otsuyama; Xu Zheng
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

6.  Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib.

Authors:  Noriyoshi Iriyama; Katsuhiro Miura; Yoshihiro Hatta; Sumiko Kobayashi; Yoshihito Uchino; Daisuke Kurita; Hitomi Sakagami; Hiromichi Takahashi; Masashi Sakagami; Yujin Kobayashi; Masaru Nakagawa; Shimon Ohtake; Yoshikazu Iizuka; Masami Takei
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

Review 7.  Immunophenotyping in multiple myeloma and related plasma cell disorders.

Authors:  Shaji Kumar; Teresa Kimlinger; William Morice
Journal:  Best Pract Res Clin Haematol       Date:  2010-09       Impact factor: 3.020

8.  The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells.

Authors:  Qun Zhou; Yuan Yao; Solveig G Ericson
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

9.  The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.

Authors:  Wilson I Gonsalves; Michael M Timm; S Vincent Rajkumar; William G Morice; Angela Dispenzieri; Francis K Buadi; Martha Q Lacy; David Dingli; Nelson Leung; Prashant Kapoor; Robert A Kyle; Morie A Gertz; Shaji K Kumar
Journal:  Leuk Res       Date:  2016-03-10       Impact factor: 3.156

10.  Characterization of clonogenic multiple myeloma cells.

Authors:  William Matsui; Carol Ann Huff; Qiuju Wang; Matthew T Malehorn; James Barber; Yvette Tanhehco; B Douglas Smith; Curt I Civin; Richard J Jones
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.